Source comparison
Melanotan-1 Melanogenesis Stimulation: Peptide Comparison
Understanding Melanotan-1's melanogenic profile requires comparison with related peptides and endogenous ligands. The table below contrasts Melanotan-1 with α-MSH, Melanotan-2 (MT-2), and afamelanotide (Scenesse®), highlighting receptor selectivity, melanogeni
This comparison does not assign a generated winner or score.
- Understanding Melanotan-1's melanogenic profile requires comparison with related peptides and endogenous ligands. The table below contrasts Melanotan-1 with α-MSH, Melanotan-2 (MT-2), and afamelanotide (Scenesse®), highlighting receptor selectivity, melanogenic potency, and clinical or research applications.
- | Peptide/Ligand | MC1R Binding Affinity (Ki, nM) | Half-Life | Melanogenic Potency (vs α-MSH) | Receptor Selectivity | Primary Research/Clinical Use | Bottom Line ||—|—|—|—|—|—|| α-MSH (endogenous) | 0.2–1.5 | <5 min | 1× (baseline) | MC1R selective (also binds MC3R, MC4R at higher concentrations) | Endogenous melanogenesis, POMC cleavage product | Rapidly degraded; short-acting; serves as reference standard for melanogenic assays || Melanotan-1 | 0.3–2.1 | 30–40 min | 10–100× (dose-dependent) | Highly MC1R selective, minimal MC3R/MC4R activity | Melanogenesis research, photoprotection studies, EPP treatment (as afamelanotide) | Enzymatically stable; prolonged MC1R activation; eumelanin-favoring; research-grade peptide || Melanotan-2 (MT-2) | 0.5–3.0 (MC1R); also MC3R, MC4R | 30–60 min | 50–1000× (pan-melanocortin agonist) | Non-selective (activates MC1R, MC3R, MC4R, MC5R) | Broad melanocortin research; sexual dysfunction models; appetite regulation | Higher melanogenic potency but no
- Melanotan-1 and afamelanotide are structurally identical—afamelanotide is the International Nonproprietary Name (INN) for Melanotan-1 when used in pharmaceutical contexts. The FDA-approved Scenesse® implant delivers afamelanotide via controlled release over 60 days, maintaining plasma concentrations sufficient for sustained melanogenesis in EPP patients, who experience severe phototoxic reactions and require elevated baseline pigmentation for photoprotection.
- Melanotan-2 differs structurally from Melanotan-1 by a single lactam bridge (cyclization between positions 4 and 10), which increases lipophilicity and receptor promiscuity. MT-2 activates MC3R and MC4R in addition to MC1R, producing appetite suppression, increased sexual arousal, and altered energy expenditure—effects mediated by hypothalamic melanocortin signaling. While MT-2 demonstrates higher melanogenic potency on a per-mole basis, its non-selective receptor activation introduces confounding physiological effects that limit its use in pure melanogenesis research. For studies isolating MC1R-mediated melanogenesis, Melanotan-1 remains the preferred tool.
- Dose equivalence is context-dependent. In vitro melanogenesis assays typically use 10–100 nM Melanotan-1 to achieve near-maximal tyrosinase induction without receptor oversaturation. Clinical trials for EPP administered afamelanotide at 16 mg per subcutaneous implant, achieving plasma concentrations estimated at 5–15 nM sustained over weeks—far below the in vitro saturation threshold but sufficient for cumulative melanogenic activation. Our synthesis protocols for Melanotan 1 provide lyophilized peptide at >98% purity, allowing researchers to prepare precise molar concentrations for dose-response studies without ambiguity introduced by peptide degradation or sequence heterogeneity.